King Pharmaceuticals Inc. (KG) Stock Research, Analysis & News

Quick Analysis on King Pharmaceuticals Inc. (KG) Stock as of November 22, 2018

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about King Pharmaceuticals Inc. (KG) Stock below)

King Pharmaceuticals Inc. (KG) Stock Profile Summary

King Pharmaceuticals, Inc. research and develops, manufactures, markets, and sells branded prescription pharmaceutical products and animal health products worldwide. It offers branded prescription pharmaceuticals, which include neuroscience products, such as Skelaxin, Flector Patch, Avinza, and Embeda; hospital products, including Thrombin-JMI; and legacy products consisting of Levoxyl, Bicillin, Altace, and Cytomel to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons, and hospitals. The companys animal health business focuses on medicated feed additives and water-soluble therapeutics, which are anti-infective products primarily for poultry, cattle, and swine markets. King Pharmaceuticals also manufactures and markets pharmaceutical products that are delivered using an auto-injector to commercial and government markets. Its auto-injector products include EpiPen, an auto-injector filled with epinephrine for the treatment of anaphylaxis resulting from severe or allergic reactions to insect stings or bites, foods, drugs, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; the nerve agent antidotes, including AtroPen and ComboPen; and the Antidote Treatment Nerve Agent Auto-injector. The company also licenses rights to third-party pharmaceutical companies to manufacture and market adenosine-based products, Adenoscan. Adenoscan is a sterile, intravenous solution of adenosine administered intravenously as an adjunct to imaging agents used in cardiac stress testing of patients. King Pharmaceuticals distributes its branded pharmaceutical products through wholesale pharmaceutical distributors, as well as animal health products through sales force. The company was founded in 1993 and is based in Bristol, Tennessee.

King Pharmaceuticals Inc. (KG) Stock Key Statistics Research and Analysis as of November 22, 2018

King Pharmaceuticals Inc. (KG) Stock Competitor Research and Analysis

Cephalon Inc. (CEPH)Elan Corp. plc (ELN)
Forest Laboratories Inc. (FRX)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
Mylan, Inc. (MYL)Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)

Latest Market News on King Pharmaceuticals Inc. (KG)


Click here to find the latest news on King Pharmaceuticals Inc. (KG)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Cephalon Inc. (CEPH)
Elan Corp. plc (ELN)
Forest Laboratories Inc. (FRX)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)